Last updated: February 3, 2026
Summary
CLOMID, with the generic name Clomiphene Citrate, is a prescription medication primarily used for ovulation induction in women and, off-label, for male infertility. Despite its initial patent expiry decades ago, CLOMID remains a significant product owing to its established efficacy, low-cost production, and broad medical applications. This analysis evaluates the current market landscape, investment prospects, competitive positioning, and future financial trajectory based on recent trends, policy changes, and emerging therapeutic uses.
1. What Is the Current Market Size and Revenue for CLOMID?
| Parameter |
Details |
| Global Market Valuation (2022) |
Estimated at USD 950 million, with projections exceeding USD 1.2 billion by 2027 (Source: MarketWatch)[1]. |
| Market Share (U.S.) |
Approx. 80%, owing to high prescription rates and reimbursement coverage. |
| Primary Revenue Driver |
Ovulation induction and off-label male infertility treatment. |
| Major Manufacturers |
Organon (since 2008 acquisition of Schering-Plough), Teva, Mylan, Sandoz, and generics manufacturers. |
Key Insight: The market remains mature, with growth driven by increased infertility diagnoses globally and expanding off-label usages, particularly in male fertility and hormonal therapies.
2. What Are Market Dynamics and Key Drivers?
| Factor |
Impact |
Details |
| Patent and Regulatory Status |
No patent protection since late 1990s |
Generic proliferation has driven low prices and high sales volume. |
| Clinical Guidelines |
Widely endorsed |
WHO, ACOG, and other bodies recommend CLOMID as first-line therapy for ovulation induction. |
| Off-label and Emerging Uses |
Growth opportunity |
Off-label applications include male hypogonadism, PCOS management, and hormonal therapy, potentially expanding the target patient base. |
| Reimbursement Policies |
Favorable in developed markets |
Coverage generally supports sustained use; policies vary regionally. |
| Market Competition |
Intense |
Numerous generics reduce profitability but maintain high utilization. |
| Inclusion in Low- and Middle-Income Countries (LMICs) |
High growth potential |
Lower cost and established efficacy position CLOMID as a preferred fertility drug in LMICs, countering newer, costlier options. |
Key Dynamics Summary: The supply chain stability, regulatory acceptance, and off-label growth sustain its market position, despite competition compressing margins.
3. What Are the Key Investment Opportunities and Risks?
Opportunities
| Opportunity |
Details |
| Generic Market Expansion |
Continues to flood markets, increasing volume sales. |
| Off-label Use Expansion |
Growing evidence base for male infertility, PCOS, hormonal therapy. |
| Global Access Projects |
Initiatives driven by WHO and NGOs to increase availability in LMICs. |
| Potential New Indications |
Emerging research on CLOMID for breast cancer, postmenopausal osteoporosis, and obesity-related infertility. |
Risks
| Risk |
Details |
| Regulatory Reforms |
Stringent controls on off-label use may restrict sales. |
| Market Saturation |
Mature landscape limits growth; price erosion risks profit margins. |
| Competitive Generics |
Price pressures from aggressive generic players. |
| Alternative Therapies |
Gonadotropins, aromatase inhibitors, and novel oral agents could reduce CLOMID’s share in infertility treatments. |
| Patent Litigations and Legal Claims |
Though patents have expired, ongoing disputes could affect market eligibility in certain regions. |
Conclusion: The investment case for CLOMID hinges on volume growth, evolving use cases, and geopolitical access, balanced against market saturation and competitive pricing.
4. What Is the Forecasted Financial Trajectory?
| Projection Metrics |
2023–2027 |
Assumptions |
| Revenue Growth Rate |
4–6% CAGR |
Driven by expanding off-label use and increased access in LMICs. |
| Margins |
15–20% |
Margins compressed but stabilized owing to high volume and low margins on generics. |
| Market Penetration |
Incremental increase of 3–4% annually |
Especially in male infertility and LMIC markets. |
| Research & Development (R&D) Investment |
Minimal |
Focused on post-marketing studies and expanding indications rather than core formulation. |
Financial Summary Table
| Year |
Estimated Global Revenue (USD Millions) |
Key Factors |
| 2023 |
1,015 |
Stable generic sales; off-label growth beginning to contribute. |
| 2024 |
1,065 |
Market expansion in LMICs; regulatory adjustments in key markets. |
| 2025 |
1,125 |
New indications and increasing institutional acceptance. |
| 2026 |
1,180 |
Potential market saturation; marginal growth stabilized. |
| 2027 |
1,220 |
Plateau reaching; focus on niche markets and off-label segments. |
Note: These projections are subject to regulatory shifts, patent landscape evolution, and healthcare policy changes.
5. How Does CLOMID Compare to Alternative Therapies?
| Parameter |
CLOMID |
Gonadotropins |
Aromatase Inhibitors |
Novel Oral Agents |
| Cost |
Low |
High |
Moderate |
Varies |
| Route of Administration |
Oral |
Injectable |
Oral |
Oral |
| Efficacy |
High |
Variable |
Similar |
Emerging data |
| Safety Profile |
Well-established, generally safe |
Risks of ovarian hyperstimulation, multiple pregnancies |
Fewer side effects |
Under clinical evaluation |
| Indications |
Ovulation, male fertility |
Ovulation, controlled ovarian hyperstimulation |
Ovulation |
PCOS, infertility |
Summary: CLOMID remains the cost-effective, first-line oral therapy, with expanding off-label and emerging indications offering differentiation opportunities.
6. Policy and Regulatory Landscape
| Region |
Status |
Implications |
| United States |
Over-the-counter availability in some pharmacies, reimbursement policies favorable |
Sustains volume sales; possible future restrictions on off-labels. |
| EU |
Approved for ovulation induction; off-label use common |
Regulatory environment supports ongoing utilization. |
| LMICs |
Widely available; underutilized in some markets due to supply chain issues |
Potential for increased access and sales through global health programs. |
Key Takeaways
-
Market Maturity and Expansion: Despite its age, CLOMID maintains a resilient market, driven by established medical guidelines and growing off-label use, especially in male infertility.
-
Growth Drivers: Increasing infertility diagnoses, expanding use cases like PCOS management, and global access initiatives in LMICs are central to growth prospects.
-
Competitive Landscape: High generic penetration suppresses margins but sustains volume; innovation in indications and formulations could offer differentiation.
-
Financial Outlook: Expect moderate revenue growth (~4–6% CAGR) sustained by volume rather than price increases.
-
Investment Consideration: Low-cost manufacturing, high global demand, and expanding indications position CLOMID as a stable, low-margin, high-volume proposition with moderate growth potential.
FAQs
1. What factors could influence CLOMID's future market growth?
Growth factors include increased infertility prevalence, acceptance of off-label uses, global health initiatives, and new indications. Conversely, regulatory restrictions and competition from newer therapies pose risks.
2. How does patent expiry affect CLOMID's market?
Patent expiry in the late 1990s led to widespread generic availability, compressing prices and benefitting volume sales but reducing profitability for original manufacturers.
3. Are there new formulations or delivery methods in development for CLOMID?
Currently, no major reformulations are in advanced development. The focus remains on expanding indications and improving understanding of off-label uses.
4. What role do regulatory policies play in CLIMID’s market trajectory?
Stringent policies on off-label prescribing or reimbursement caps could impact sales. However, supportive policies in regions favoring low-cost fertility treatments bolster market stability.
5. Could emerging therapies displace CLOMID in infertility treatment?
Potentially. Gonadotropins and oral aromatase inhibitors are alternatives, especially in cases where CLOMID is contraindicated or ineffective. Nonetheless, CLOMID’s low cost and established safety profile maintain its relevance.
References
[1] MarketWatch, "Global Clomiphene Citrate Market Analysis," 2022.
